<DOC>
	<DOCNO>NCT00220285</DOCNO>
	<brief_summary>The purpose study investigate antitumor effect safety product relapse refractory indolent B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study Evaluation Efficacy Safety SH L 749 Indolent B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Platelet count &gt; /= 100,000/mm3 Absolute neutrophil count &gt; /= 1,200/mm3 Bone marrow involvement &lt; 25 % Patients receive hematopoietic stem cell transplantation , include bone marrow transplantation , peripheral blood stem cell transplantation , etc . Patients present mark bone marrow hypocellularity ( suspect bone marrow hypocellularity confirm bone marrow biopsy ) Patients previous myocardial infarction within past 1 year , heart disease require treatment pulmonary dysfunction Patients serious concomitant disease ( cardiac failure , renal failure , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigen</keyword>
	<keyword>CD20</keyword>
</DOC>